These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18473869)

  • 1. The blockade of IL-6 signaling in rational drug design.
    Adachi Y; Yoshio-Hoshino N; Nishimoto N
    Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting interleukin-6 in rheumatoid arthritis.
    Choy E
    Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
    Nishimoto N
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab.
    Venkiteshwaran A
    MAbs; 2009; 1(5):432-8. PubMed ID: 20065633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
    Ding C; Jones G
    Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [IL-6 targetting therapy for inflammatory immune diseases].
    Nishimoto N
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1795-800. PubMed ID: 17037317
    [No Abstract]   [Full Text] [Related]  

  • 9. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
    Paul-Pletzer K
    Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
    Ohsugi Y
    Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology evaluation: MRA, Chugai.
    Ding C; Jones G
    Curr Opin Mol Ther; 2003 Feb; 5(1):64-9. PubMed ID: 12669473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of IL-6 and Development of Anti-IL-6R Antibody.
    Kishimoto T
    Keio J Med; 2019; 68(4):96. PubMed ID: 31875623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.